Kusajili – Centralise les essais cliniques mondiaux

Résultat de votre recherche par promoteur : Merck Serono S.A.-Geneva, an affiliate of Merck KGaA Darmstadt, Germany

Femme et Homme Max 99 ans
Merck Serono S.A.-Geneva, an affiliate of Merck KGaA Darmstadt, Germany MAJ Il y a 4 ans

A randomised, double-blind, placebo-controlled, multicentre prospective dose-finding Phase II/III study with atacicept given subcutaneously to subjects having recently experienced a flare of systemic lupus erythematosus (SLE) The primary objective of this trial is to evaluate the efficacy of atacicept compared to placebo in preventing new flares in subjects with SLE.

Pays Aucun
Organes Aucun
Spécialités Aucune

Essai clos aux inclusions

Plus d'informations

Femme et Homme Max 99 ans
Merck Serono S.A.-Geneva, an affiliate of Merck KGaA Darmstadt, Germany MAJ Il y a 4 ans

A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis The primary objective of the study is to evaluate the effect of Rebif New Formulation 44 mcg (tiw and ow) versus placebo on the time to conversion to McDonald MS in patients with a first clinical demy...

Pays Aucun
Organes Aucun
Spécialités Aucune

Essai clos aux inclusions

Plus d'informations